Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma.
Malignant cells constitutively express Natural killer group 2, member D (NKG2D) or DNAX Accessory Molecule-1 (DNAM-1) ligands, yet they are often unable to trigger a robust cytotoxic cell response. It may be therapeutically useful to implement strategies aimed at increasing the density of NKG2D and DNAM-1 ligands on the surface of cancer cells, endowing them with the capacity to activate potent antitumor natural killer-cell responses.
Department of Molecular Medicine; Instituto Pasteur-Fondazione Cenci Bolognetti; Sapienza University of Rome; Rome, Italy.
Alessandra
A
Soriani
Department of Molecular Medicine; Instituto Pasteur-Fondazione Cenci Bolognetti; Sapienza University of Rome; Rome, Italy.
Cinzia
C
Fionda
Department of Molecular Medicine; Instituto Pasteur-Fondazione Cenci Bolognetti; Sapienza University of Rome; Rome, Italy.
Biancamaria
B
Ricci
Department of Molecular Medicine; Instituto Pasteur-Fondazione Cenci Bolognetti; Sapienza University of Rome; Rome, Italy.
Maria Luisa
ML
Iannitto
Department of Molecular Medicine; Instituto Pasteur-Fondazione Cenci Bolognetti; Sapienza University of Rome; Rome, Italy.
Marco
M
Cippitelli
Department of Molecular Medicine; Instituto Pasteur-Fondazione Cenci Bolognetti; Sapienza University of Rome; Rome, Italy.
Angela
A
Santoni
DNAM-1; NK cells; NKG2D; multiple myeloma; tumor immunology